media – Page 130 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

The First Drug to Treat Infants Sick With Malaria Is Approved by Swiss Authority

GENEVA (AP) — Switzerland’s medical products authority has granted the first approval for a malaria medicine designed for small infants, touted as an advance against a disease that takes hundreds of thousands of lives — nearly all in Africa — each year. Swissmedic gave a green light Tuesday for the medicine from Basel-based pharmaceutical company Novartis for treatment of babies with body weights between 2 and 5 kilograms (nearly 4½ to 11 pounds), which could pave the way for hard-hit African nations to follow suit in coming months. The agency said that the decision is significant in part because it’s only the third time it has approved a treatment under a fast-track authorization process, in coordination with the World Health Organization, to help developing countries access needed treatment. The newly approved medication, Coartem Baby, is a combination of two antimalarials. It is a lower dose version of a tablet ...
- Source: drugdu
- 158
- July 10, 2025
Medical Japan Osaka

Organiser: RX Japan Ltd. Time：March 10-12, 2026 address：1-5-102 Nanko-Kita, Suminoe-ku, Osaka, 559-0034 Japan Exhibition hall：Intex Osaka Product range: Medical Equipment: Medical electronic instruments, ultrasonic instruments, X-ray equipment, medical optical instruments, clinical laboratory analytical instruments, dental equipment and materials, hemodialysis equipment, anesthesia and respiratory equipment, etc.; disposable medical supplies, dressings, and hygienic materials, various surgical instruments. Medical Supplies: Medical electronic instruments, medical ultrasonic instruments, medical X-ray equipment, medical optical instruments, clinical laboratory analytical instruments, dental equipment and materials, operating room, emergency room, and consultation room equipment and appliances, diagnostic equipment and supplies, disposable medical supplies, medical dressings, and hygienic materials, various surgical instruments, medical health care equipment and supplies, traditional Chinese medical instruments and rehabilitation devices, hemodialysis equipment, anesthesia and respiratory equipment, etc.; home health care products, small home diagnostic, monitoring, and treatment instruments, rehabilitation and physiotherapy instruments and supplies, electronic medical instruments, dental tools, hospital office supplies, sports medicine supplies. ...
- Source: drugdu
- 279
- July 10, 2025
Which Strength Training Method Is Best for You? Experts Break Down the Options

When it comes to weight-resistance exercise, you can choose free weights such as dumbbells or barbells. Or weight machines, which are often driven by cables or levers. You can use resistance bands or tubes to build strength. Or try pushups and pullups — old standbys that create muscle overload by using your own body weight. These four basic options for strength training present fitness possibilities for young or old or beginners. And they offer flexibility for use in the gym, your home or in a hotel room during travel. You’ll probably wind up using a combination of the four, and they all have their pros and cons. They are appropriate for all ages and can be augmented with aerobic exercises like walking or running — or even climbing stairs. Let’s let Dr. Rafael Escamilla, a biomechanist and physical therapist at Sacramento State University in California, and Dr. Michael Stone, a ...
- Source: drugdu
- 156
- July 9, 2025
Is One Type of Water Healthier Than Another? Here’s What Experts Say

SUNDAY, July 6, 2025 (HealthDay News) — Alkaline. Electrolyte. Flavored. Walk down the beverage aisle and you’ll find all kinds of waters promising extra health perks. But are these fancy waters really better for you? Not really, Tufts University experts say. “There’s no physiological basis that there’s some metabolic benefit to these specialty waters over just regular, plain old water,” said Roger Fielding, a senior scientist at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts in Boston. For most people, Fielding said the best thing to do is simply drink more fluids — especially since many people walk around mildly dehydrated. “If you have a preference for a beverage and that’s going to make you drink more and you’ll be more attentive to rehydrating with that beverage, and you have the resources to purchase that beverage, well have at it,” Fielding said in a news release. ...
- Source: drugdu
- 151
- July 9, 2025
【EXPERT Q&A】How effective is Dula peptide in lowering blood sugar?

Drugdu.com expert’s response: Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with significant glucose-lowering effects, particularly suitable for patients with type 2 diabetes mellitus. Its specific manifestations are as follows: I. Core Glucose-Lowering Mechanisms Promotion of Insulin Secretion: By mimicking the body’s natural GLP-1, dulaglutide activates GLP-1 receptors, increasing cyclic adenosine monophosphate (cAMP) levels in pancreatic β-cells. This precisely stimulates insulin secretion when blood glucose levels rise (e.g., after meals), thereby lowering blood glucose. Inhibition of Glucagon Release: Glucagon is a hormone that raises blood glucose. Dulaglutide suppresses its secretion, further reducing hepatic glucose output and aiding in glycemic control. Delay of Gastric Emptying: By slowing the passage of gastric contents into the small intestine, dulaglutide prolongs carbohydrate absorption time, preventing sharp postprandial blood glucose spikes and achieving stable glycemic control. II. Clinical Efficacy Data Significant Reduction in Glycated Hemoglobin (HbA1c): Multiple studies demonstrate that after 24 weeks of dulaglutide treatment, HbA1c levels decrease by ...
- Source: drugdu
- 236
- July 9, 2025
SALMED

Organiser: Poznań International Exhibition Company Time：May 19-20, 2026 address：Głogowska 14, 60-734 Poznań, Poland Exhibition hall：Poznan International Fair MTP Product range: Medical Devices: Medical equipment and instruments, medical rescue and emergency pharmaceutical special vehicles, equipment and instruments, laboratory equipment, rehabilitation and physiotherapy equipment, healthcare facility construction technology, medical communication equipment, and information technology. Medical Supplies and Services: Disposable materials, medical sterilization, cleaning, and disposal, as well as medical-related services. About SALMED： The Poland Poznań Medical Equipment Exhibition (SALMED) is Poland’s most significant exhibition for medical devices and instruments. Established in 1973, it is also one of the largest medical equipment and instrument exhibitions in Central and Eastern Europe and a key recommended event by the Polish Chamber of Exhibition Industry.
- Source: drugdu
- 231
- July 8, 2025
Innovent Biologics’ Suvicitamab is approved for marketing, solving the dilemma in the treatment of platinum-resistant ovarian cancer

On July 3, 2025, Innovent Biologics, an innovative drug subsidiary of Innovent Biologics (2096.HK), announced that its new generation VEGF-targeted antibody drug Enzeshu® (Suvixitamab) developed in China was approved for marketing by the National Medical Products Administration (approval number: National Medicine Standard S20250037, approval date June 30, 2025), becoming the first targeted therapy in China to cover the entire population of platinum-resistant ovarian cancer. The drug is indicated for combined chemotherapy for the treatment of recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has failed platinum-containing treatment, filling the clinical gap in targeted therapy in this field in my country. This is also the second innovative drug approved for marketing in the innovative pipeline of Innovent Biologics in 2025, following Dalireson. 01 Double survival benefit breaks through the treatment dilemma of platinum-resistant ovarian cancer The approval of Enzeshu® is based on the world’s first Phase III study ...
- Source: drugdu
- 517
- July 7, 2025
Everest Medicines’ Next-Generation BTK Inhibitor EVER001 Announces Latest Clinical Results, Continues to Demonstrate Efficacy and Safety

On July 2, Everest Medicines (1952.HK), a Hong Kong-listed innovative pharmaceutical company, announced that its new generation of covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor EVER001 (XNW1011), for which it has global rights, has obtained positive latest interim data in a Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN). The data showed that EVER001 continued to demonstrate excellent efficacy and safety during the extended follow-up period. Driven by these excellent clinical data, the development of EVER001 is expected to accelerate. Based on the current positive clinical data, experts recommend communicating directly with the U.S. Food and Drug Administration (FDA) to initiate Phase III clinical studies, and simultaneously communicate with the China Food and Drug Administration (CDE). Clinical trial data highlights frequently, with both effectiveness and safety According to reports, the Phase 1b/2a clinical trial of EVER001 for the treatment of primary membranous nephropathy conducted in China ...
- Source: drugdu
- 320
- July 7, 2025
Jinsai Pharmaceutical’s Fuxin Qibaimab was approved, reducing the risk of gout recurrence by 87% in half a year

Recently, the official website of the National Medical Products Administration (NMPA) announced that Jinbeixin (Fuxinqibaimab), a Class 1 innovative drug independently developed by Jinsai Pharmaceutical, has been officially approved for marketing. It is suitable for patients with acute attacks of gouty arthritis in adults who are contraindicated, intolerant or ineffective to non-steroidal anti-inflammatory drugs and/or colchicine, and who are not suitable for repeated use of steroid hormones. With the three major clinical advantages of ” long-term control, rapid and effective, and safe and reliable “, Jinbeixin is expected to become the largest single product in the field of autoimmune disease treatment in China, meet huge market demand, and escort the majority of gout patients! Gout is known as the “king of pain”. According to the “2021 China Hyperuricemia and Gout Trend White Paper”, there are approximately 177 million patients with hyperuricemia in China, and more than 14.66 million patients with ...
- Source: drugdu
- 311
- July 7, 2025
LH-1801 project enters Phase III clinical trial

On July 3, Lianhuan Pharmaceutical(600513) announced that the company has recently conducted a specific object survey with a number of investment institutions. The event was held in Beijing on July 2, 2025, and the participating units included China Asset Management, China Canada Fund and Shibei Investment. The company’s director and general manager Niu Ben and the director of the board office Ge Kai received investors and introduced the company’s development history, technical cooperation and the progress of the projects under research. The LH-1801 project mentioned in the announcement is an SGLT2 inhibitor jointly developed by the company and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The project has now entered the Phase III clinical trial stage. It is expected that key data will be obtained in the first quarter of next year and an application for listing will be submitted to the National Medical Products Administration in ...
- Source: drugdu
- 776
- July 7, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.